TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01529008
Drug: Core decompression/PREOB® implantation
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will undergo a core decompression under general anesthesia combined with the implantation of PREOB® into the necrotic lesion (single administration).
Study: NCT01529008
Drug: Core decompression/placebo implantation
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will undergo a core decompression under general anesthesia combined with the implantation of placebo into the necrotic lesion (single administration).
Study: NCT00147901
Drug: FCCam
Approvals — FDA: no, EMA: no, PMDA: no
Description: After an initial subcutaneous dose escalation of alemtuzumab over 2 days, 30 mg alemtuzumab s.c., cyclophosphamide 200 mg/m2 i.v. and 25 mg/m2 fludarabine i.v. were administered on three consecutive days. Treatment was repeated after 28 days for up to six cycles
Study: NCT00224770
Drug: MIS+Cathflo Activase (drug)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIS+Cathflo Activase (drug): The intervention is a comparison of the safety and preliminary effectiveness of investigational minimally invasive surgery to place a catheter into an intracerebral hemorrhage blood clot and subsequent administration in sequential tiers of 0.3 or 1.0mg of rt-PA, CathFlo® through the catheter once every eight hours for up to 72 hours, in addition to best medical care.
Study: NCT01238718
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline
Study: NCT03588078
Drug: APR-246
Normalized name: PrameGel Reformulated Apr 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azacitidine at maximum tolerated dose. APR246 at the Dose limited Toxicity (DLT) dose
Study: NCT00602290
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills will be taken in combination with the active pills. Participants will initially take 1 capsule twice per day, which will be increased to a maximum of 16 capsules twice per day matching methylphenidate, and 1-3 capsules matching citalopram. After Visit 11, placebo dosage will be gradually reduced over 2 weeks until participants are no longer taking any capsules.
Study: NCT02229929
Drug: Part A: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: Single i.v. dose of Placebo administered after each dialysis session over a 1 week treatment period (3 times per week)
Study: NCT02229929
Drug: Part A: CR845 0.5 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
Study: NCT02229929
Drug: Part A: CR845 1.0 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
Study: NCT02229929
Drug: Part A: CR845 2.5 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
Study: NCT02229929
Drug: Part B: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part B: Single i.v. dose of Placebo administered after each dialysis session over a 2 week treatment period (3 times per week)
Study: NCT02229929
Drug: Part B: CR845 1.0 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part B: Single i.v. dose of CR845 administered after each dialysis session over a 2 week treatment period (3 times per week)
Study: NCT00799331
Drug: AZD5985
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension. Single oral doses of AZD5985 starting with 4 mg and subsequently with up to 3 dose escalations will be administered not exceeding AstraZeneca pre-defined upper exposure limits.
Study: NCT02071810
Drug: BIA 9-1067
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00799331
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension.
Study: NCT01537068
Drug: Desvenlafaxine
Normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desvenlafaxine oral dose ranging from 50 to 100 mg/day
Study: NCT01537068
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo pills
Study: NCT04245722
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lympho-conditioning agent
Study: NCT01742585
Drug: ASP1585
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01742585
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00458510
Drug: Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: treatment of up to 4 episodes of pain per day
Study: NCT01312714
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 tablets of 1000 IU daily for 26 weeks
Study: NCT00951834
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00409747
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03858556
Drug: Herbal medicine
Normalized name: Herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
Study: NCT00383695
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02783599
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered IV
Study: NCT02767661
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine, 500mg, orally three times daily (continuously)
Study: NCT02767661
Drug: Aromatase Inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase Inhibitor (Anastrozole, 1mg, orally once daily or Letrozole, 2.5mg, orally once daily or Exemestane , 25mg, orally once daily)
Study: NCT00839085
Drug: Vit C (Ascorbic Acid)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vit C 25 mg/ kg
Study: NCT02451072
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing mannitol looking identical to LSD per os
Study: NCT04471298
Drug: Qishenyiqi dripping pills, 9 bags
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 consecutive days
Study: NCT04471298
Drug: Qishenyiqi dripping pills, 12 bags
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 consecutive days
Study: NCT04471298
Drug: Qishenyiqi dripping pills placebo, 6 bags
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 consecutive days
Study: NCT04471298
Drug: Qishenyiqi dripping pills placebo, 9 bags
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 consecutive days
Study: NCT04471298
Drug: Qishenyiqi dripping pills placebo, 12 bags
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 consecutive days
Study: NCT01786824
Drug: Hydration strategy using saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: For 12 hours preceding the coronarography, and for 12 following the coronarography, 0.9% sodium chloride at 1 ml/kg/h is administered via a slow intravenous perfusion.
Study: NCT03090724
Drug: BIA 5-453
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of BIA 5-453 (combination of two 50 mg capsules); Oral, once-daily (QD), in the morning in fasting conditions
Study: NCT00425971
Drug: BMEC-1217B
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01323244
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=150, form=capsule, route=oral use, once daily for 12 weeks in addition to peginterferon alfa-2a peginterferon and ribavirin for 24 or 48 weeks
Study: NCT02288078
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule filled with lactose
Study: NCT02288078
Drug: Proton pump inhibitor
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPIs (omeprazole, lansoprazole, etc, as not specified) for prevention of peptic ulcer
Study: NCT00201461
Drug: Best medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin (325 mg daily) and/or warfarin (target INR = 2.5)
Study: NCT01037127
Drug: GSK1120212
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral dosing
Study: NCT03071731
Drug: Bronchodilators
Normalized name: ANTIASTHMA/BRONCHODILATORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a nebulized combination of bronchodilators before the administration of a functional test.
Study: NCT03071731
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a nebulized placebo before the administration of a functional test
Study: NCT01362244
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo by IV infusion
Study: NCT02790788
Drug: Methylprednisolone; hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 40 mg during resuscitation and stress-dose hydrocortisone for postresuscitation shock
Study: NCT02790788
Drug: Saline Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo during resuscitation and during the postresuscitation phase.
Study: NCT01450774
Drug: CHF 1535 50/6µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: fixed combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg
Study: NCT02191176
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00264160
Drug: AMN107
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02464891
Drug: CCX168
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004935
Drug: Herceptin™ (Her)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks; at time of progression add chemotherapy
Study: NCT00004935
Drug: Herceptin™ (Her) + chemo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks, and chemotherapy
Study: NCT03335423
Drug: Oral codeine and oral metformin
Normalized name: metformin and ertugliflozin
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases. Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin. Metformin was given alone and together with codeine to investigate a potential interaction between the drugs. Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin
Study: NCT03335423
Drug: Oral codeine and intravenous metformin
Normalized name: metformin and ertugliflozin
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases. Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin. Metformin was given alone and together with codeine to investigate a potential interaction between the drugs. Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin
Study: NCT03439189
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo versus emricasan in Conatus NASH treatment trial
Study: NCT04500860
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drugs
Study: NCT02522013
Drug: isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03837093
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections starting with induction course with once-daily administration for 5 consecutive days, followed by maintenance course with once every weeks administration during three weeks
Study: NCT05125549
Drug: Сlopidogrel bisulfate film-coated tablets, 75 mg (JSC Farmak, Ukraine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One film-coated tablet was administrated orally with 240 ml of water after an overnight fast
Study: NCT05125549
Drug: Plavix® 75 mg film-coated tablets (Sanofi Winthrop Industrie, France)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One film-coated tablet was administrated orally with 240 ml of water after an overnight fast
Study: NCT03386032
Drug: Investigational OTC Cream
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational Over the Counter (OTC) Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as moisturizer.
Study: NCT02111499
Drug: LAS41004-IMP1
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily topical application
Study: NCT02111499
Drug: LAS41004 IMP2
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily topical application
Study: NCT02111499
Drug: LAS41004 IMP3
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily topical application
Study: NCT02111499
Drug: LAS41004 IMP4
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily topical application
Study: NCT02111499
Drug: LAS41004 IMP5
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily, topical
Study: NCT01821040
Drug: Lodotra®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lodotra, starting dose of 15mg administered in the evening
Study: NCT03032965
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subject will receive 6-24 mg of intravenous adenosine given rapidly for each PV in order to assess dormant PV conduction.~Subjects in this group will also receive isoproterenol to assess inducibility of AF with re-isolation of PVs and targeting non PV sources of AF if necessary.Isoproterenol will be infused through a femoral vein at rates of 5, 10, 15, and 20 μg/min for 2 minutes at each infusion rate.
Study: NCT02209805
Drug: BIRB 796 BS, high dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02209805
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03813147
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intrathecally
Study: NCT03813147
Drug: Therapeutic Hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given intrathecally
Study: NCT01063920
Drug: Naprosyn®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg b.i.d. p.o. for 12 weeks
Study: NCT02916602
Drug: HCP1401
Approvals — FDA: no, EMA: no, PMDA: no
Description: amlodipine, Losartan, Chlorthalidone FDC
Study: NCT02916602
Drug: HCP0605
Approvals — FDA: no, EMA: no, PMDA: no
Description: amlodipine, Losartan FDC
Study: NCT00485225
Drug: EN3270
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal Therapeutic System
Study: NCT04659382
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: standard chemotherapy for first line treament of metastatic CRC (in pMMR and/or MSS patients)
Study: NCT03806231
Drug: Outpatient Dinoprostone 10mg
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dinoprostone (10 mg) is a vaginal insert approved to start and/or continue the ripening of the cervix in pregnant women who are at or near the time of delivery and in whom there is a medical reason for inducing (bringing on) labor. Women randomized to the outpatient cervical ripening group will be administered the drug prior to their induction and discharged after monitoring and physician approval. They will return for their schedule induction.
Study: NCT01184105
Drug: Intervention B
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dose of placebo will consist of 6 sprays of the placebo spray applied topically to cervix (2 sprays) and vaginal fornices (4 sprays)
Study: NCT03806231
Drug: Inpatient Dinoprostone 10 mg
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dinoprostone (10 mg) is a vaginal insert approved to start and/or continue the ripening of the cervix in pregnant women who are at or near the time of delivery and in whom there is a medical reason for inducing (bringing on) labor. Women who are randomized to the inpatient cervical ripening group will be administered the drug prior to their induction and remain hospitalized.
Study: NCT04106050
Drug: BIIB095
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT04106050
Drug: BIIB074
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT04106050
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT03996408
Drug: TQB2450
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Study: NCT02953106
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray
Study: NCT03221842
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excipients of C1-INH plus albumin
Study: NCT04608344
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as single dose tablet orally.
Study: NCT04608344
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered as single dose tablet orally.
Study: NCT03191864
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets are identical in composition to APT-1011 except they exclude the active ingredient.
Study: NCT03144843
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
Study: NCT00846703
Drug: 6-mercaptopurine, Methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-mercaptopurine p.o. qd~Methotrexate p.o. qw
Study: NCT00846703
Drug: 6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: (1)6-mercaptopurine p.o. qd x 7w Methotrexate p.o. qd x 7w~(2)Vincristine qw x 1w Dexamethasone p.o. qd x 7d~Go to (1) and (2)
Study: NCT02152553
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02152553
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01765829
Drug: Discontinuation antipsychotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reduction until withdrawal
Study: NCT01765829
Drug: Antipsychotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic treatment is not modify during the study, it is administered according to common clinical practice
Study: NCT02044874
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01563367
Drug: Natriumklorid 9 mg/ml, Fresenius Kabi
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects randomised to this group will receive an infusion of 100 ml 0.9% sodium chlorid administered over 15 min.
Study: NCT00084214
Drug: STA-4783
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01790659
Drug: Paromomycin
Normalized name: Paromomycin
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paromomycin alone
Study: NCT00778102
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400mg/m2 2-hour iv infusion, day 1 every 2 weeks
Study: NCT00778102
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200mg/m2 2-hour iv infusion, day 1 every 2 weeks
Study: NCT00779532
Drug: NOMAC-E2 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing NOMAC-E2 placebo, once daily dosing, orally taken.
Study: NCT01319279
Drug: Hydrocodone bitartrate extended-release tablet
Normalized name: hydrocodone bitartrate Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg (single dose)
Study: NCT00787917
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous injections blinded to match experimental arm dosing regimen.
Study: NCT04664946
Drug: Intra-arterial administration of neuroprotective agents
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial administration of 3-n-butylphthalide for 24 hours via microcatheter at 17.36 ug/min.
Study: NCT04516382
Drug: PTG-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug
Study: NCT02487498
Drug: QVA149
Approvals — FDA: no, EMA: no, PMDA: no
Description: QVA149 capsules for inhalation, delivered via QVA149 SDDPI
Study: NCT02487498
Drug: Placebo (QVA149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo to QVA149 capsules for inhalation, delivered via QVA149 SDDPI
Study: NCT04112160
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IM injection of either normal saline or Ketorolac
Study: NCT04112160
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline
Study: NCT03241810
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03785613
Drug: Reference Product R: Transtec patch (20 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transtec (Registered Trademark) transdermal patch containing 20 milligrams buprenorphine in an active surface area of 25 square centimeters, release rate 35 micrograms per hour.
Study: NCT03785613
Drug: Matching placebo patch to T1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch to T1.
Study: NCT03785613
Drug: Matching placebo patch to T2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch to T2.
Study: NCT03785613
Drug: Matching placebo patch to R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch to R.